Natera(US:NTRA)2024-02-28 16:00Revenue Expectations - The company expects a significant portion of its revenues to be derived from sales of Panorama, Horizon, and Signatera[13] - The company anticipates that Panorama will be adopted for the screening of microdeletions, with third-party payer reimbursement expected to support this testing[13] Financial Performance - The company has incurred net losses since inception and expects to continue incurring losses for the foreseeable future[19] - The company reported an unrealized gain of $13.3 million on available-for-sale securities for the fiscal year ending December 31, 2023[501] Debt and Interest Expenses - The company has $80.4 million gross debt outstanding on its Credit Line as of December 31, 2023, with an interest rate of 30-day SOFR average plus 0.5%[500] - An incremental change in the borrowing rate of 100 basis points would increase the company's annual interest expense by $0.8 million[497] Operational Risks - The company is exposed to foreign currency exchange rate fluctuations as it expands internationally, which may affect its results of operations[502] - The company does not currently believe that inflation has had a material effect on its business, but significant inflationary pressures could harm its financial condition[503] - The company relies on a limited number of suppliers, which may impact its ability to maintain a continued supply of laboratory instruments and materials[22] - The company has experienced rapid growth and may be unable to successfully scale its operations, which could harm its business[22]